MI HB5598

Adds definition of "biosimilar drug product" as a biological product determined by the FDA to be biosimilar and interchangeable with a reference product for indicated uses.

Allows pharmacists to dispense lower-cost generic equivalent or biosimilar drug products in place of brand-name prescriptions, with patient notification and labeling requirements.

Requires pharmacists to pass on cost savings to the purchaser or third-party payer when substituting generic or biosimilar drugs.

Prohibits substitution when prescriber writes "dispense as written" or "d.a.w." on the prescription, or when prescriber expressly indicates the prescription must be dispensed as communicated.

Prohibits pharmacists from dispensing any drug product with a total charge exceeding the originally prescribed drug unless the purchaser agrees.